You are here

  • Home
  • Archive
  • Volume 30, Issue Suppl 4
  • 518 Phase 1B trial of monalizumab (NKG2A inhibitor) plus durvalumab: safety and efficacy in patients with metastatic ovarian, cervical, and microsatellite-stable endometrial cancers

Article metrics

Article menu

Download PDFPDF

Ovarian cancer
518 Phase 1B trial of monalizumab (NKG2A inhibitor) plus durvalumab: safety and efficacy in patients with metastatic ovarian, cervical, and microsatellite-stable endometrial cancers
Free

 

Online download statistics by month:

Online download statistics by month: December 2020 to March 2023

AbstractFullPdf
Dec 2020148040
Jan 20214405
Feb 20211707
Mar 20217208
Apr 202139010
May 202135011
Jun 2021405
Jul 20212012
Aug 20211106
Sep 20214011
Oct 202176023
Nov 202171024
Dec 20215406
Jan 202249013
Feb 20228404
Mar 202211405
Apr 20221902
May 202238023
Jun 20224206
Jul 20224805
Aug 20224207
Sep 202280025
Oct 20225306
Nov 202235014
Dec 202250012
Jan 202337011
Feb 20234402
Mar 20235008
Total13620311